Alliance A221505

Clinical Trial Title Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
Trial Status Closed to Enrollment
Start Date 04/30/2018
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Breast Cancer
Description This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
Eligibility Criteria
  • Histologically confirmed invasive carcinoma of the breast
  • Patient ≥ 18 years of age
  • No prior radiation therapy to the chest, neck or axilla
  • No prior history of ipsilateral breast cancer (invasive disease or DCIS)
  • No history of prior or concurrent contralateral invasive breast cancer
  • No significant post mastectomy complications requiring an unplanned re-operation or admission for IV antibiotics
  • Radiation oncologist intends to treat all target volumes described in section 7.4 and respect all normal tissues identified in section 7.4.3 in accordance with the dosimetric constraints described
  • Patient must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 8 months after radiation
  • No other malignancy within 5 years of registration
IRB Number Central IRB
Principal Investigator Regan Look, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail